The first line hormonal therapy for this subtype of breast cancer utilizes selective estrogen receptor modulators (SERMs) such as tamoxifen, aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs), such as Fulvestrant (3). The gene discussed is CYP19A1; the disease is breast cancer.